NYR-BI03 Extends Cardioprotection to Arrhythmia Control

Highlights:
•Preclinical study demonstrates NYR-BI03 provides strong cardioprotection when administered as a short-duration intravenous infusion following myocardial infarction (heart attack).
•Study builds upon Nyrada’s earlier cardioprotection study reported in October 20241.
•Significant reductions in both heart muscle injury size and Troponin I, a key cardiac injury biomarker.
•NYR-BI03 treated animals displayed reduced incidence of ventricular arrhythmias, the leading cause of sudden cardiac death following heart attack.